Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.60 |
| ▸ | AKT2 | P31751 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417148 | 0.98 | AKT1 (0.61) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL25415908 | 0.90 | AKT1 (0.54) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL25415193 | 0.88 | AKT1 (0.52) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL25416724 | 0.88 | AKT1 (0.51) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL18776373 | 0.86 | AKT1 (0.58) | AKT1AKT2NPC1RAB9ACGAS | |
| SCHEMBL25417063 | 0.85 | AKT1 (0.46) | AKT1AKT2PLAUALDH1A1KDM4E | |
| SCHEMBL16003629 | 0.85 | AKT1 (0.58) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL25416172 | 0.83 | AKT1 (0.45) | AKT1AKT2PLAUKDM4EPTK2 | |
| SCHEMBL25416128 | 0.83 | AKT1 (0.47) | AKT1AKT2NPC1RAB9APLAU | |
| SCHEMBL20579805 | 0.81 | NPC1 (0.77) | AKT1AKT2NPC1RAB9APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071117-A1 | FUNABLE FLUORESCENT COMPOUNDS AND USES THEREOF | UNIV ARIZONA (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2023081261-A1 | TUNABLE FLUORESCENT COMPOUNDS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-9862716-B2 | TRKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170114056-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114056-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3122345-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148373-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148373-A2 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015143652-A1 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071117-A1 | FUNABLE FLUORESCENT COMPOUNDS AND USES THEREOF | H1-3, NISCH, H1-2 | AKT1 3389/4885AKT2 3506/4885NPC1 2638/4885 |
| US-20170114056-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK2 | AKT1 408/4885AKT2 776/4885NPC1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.